Serynth Milia Remover Essence

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of milia, which are small skin bumps commonly found on the face. It aids in the exfoliation of dead skin cells, contributing to the improvement of skin texture.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Healthcare professionals are advised to cleanse and dry the affected skin area thoroughly prior to application. A thin layer of the product should be applied directly onto the milia (skin bumps) once or twice daily, depending on the patient's needs. The product should be gently massaged into the skin until fully absorbed.

For optimal results, consistent use of the product for a duration of 4 weeks is recommended.

Contraindications

Use of this product is contraindicated in the following situations:

Patients whose condition worsens or does not improve within 4 weeks should discontinue use. The product should not be applied in the presence of severe redness, burning, or swelling. Additionally, it is contraindicated for use during pregnancy or breastfeeding unless advised by a healthcare professional.

Contact with eyes, lips, and mucous membranes must be avoided; in case of contact, rinse thoroughly with water. The product should not be applied to broken, irritated, or sunburned skin. Excessive drying or peeling may occur, and if severe irritation develops, use should be discontinued.

Warnings and Precautions

For external use only. It is imperative that healthcare professionals advise patients to avoid contact with the eyes, lips, and mucous membranes. In the event of contact, patients should rinse the affected area thoroughly with water. The product should not be applied to broken, irritated, or sunburned skin, as this may lead to excessive drying or peeling. Should severe irritation develop, it is recommended to discontinue use immediately.

Healthcare professionals should instruct patients to seek medical advice if their condition worsens or does not improve within four weeks of use. Additionally, patients should be advised to contact their healthcare provider if they experience severe redness, burning, or swelling. Pregnant or breastfeeding individuals should consult a health professional prior to use to ensure safety.

Side Effects

Patients using this product should be aware that it is intended for external use only. In clinical practice, if the condition being treated worsens or does not show improvement within 4 weeks, patients are advised to discontinue use and consult a healthcare professional.

Additionally, patients should seek medical advice if they experience severe redness, burning, or swelling during treatment. These reactions may indicate a more serious issue that requires attention. It is important for patients to monitor their symptoms closely and take appropriate action if any of these adverse reactions occur.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Serynth Milia Remover Essence (salicylic acid 1% milia remover essence). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. It is essential to ensure that the medication is stored safely to prevent accidental ingestion or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients.

It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population. Consideration of individual patient factors, including comorbidities and concurrent medications, is essential in managing treatment effectively in elderly patients.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully weighed, as the effects on fetal outcomes and lactation are not fully established. It is essential for women of childbearing potential to seek medical advice to ensure safe use during pregnancy and lactation.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available data regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of information necessitates careful clinical judgment and monitoring of these patients.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial for healthcare professionals to document the incident thoroughly, including the substance involved, estimated dose, time of exposure, and any interventions performed. This information is vital for ongoing patient care and for any necessary reporting to regulatory authorities.

In summary, while no specific overdosage information is provided, healthcare professionals should be prepared to respond effectively to potential overdose situations through prompt assessment, supportive care, and appropriate interventions.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. Patients should be informed that if their condition worsens or does not improve within four weeks, or if they experience severe redness, burning, or swelling, they should seek medical attention promptly.

For patients who are pregnant or breastfeeding, it is essential to recommend consulting a healthcare professional before using the medication. Providers should emphasize the importance of avoiding contact with the eyes, lips, and mucous membranes. In the event of contact, patients should be instructed to rinse the area thoroughly with water.

Additionally, healthcare providers should caution patients against applying the medication to broken, irritated, or sunburned skin. They should be made aware that excessive drying or peeling may occur, and if severe irritation develops, they should discontinue use and consult a healthcare professional.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to ensure optimal stability. Additionally, it is essential to keep the product out of reach of children to prevent accidental ingestion or misuse.

Additional Clinical Information

The product is administered topically, with a recommendation to apply a thin layer directly onto the milia (skin bumps) once or twice daily, as needed. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Serynth Milia Remover Essence, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)